Nav: Home

Exclusive: Biotechnology leaders surveyed about impact of Trump presidency

November 11, 2016

New Rochelle, Nov 11, 2016--The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by GENETIC ENGINEERING AND BIOTECHNOLGY NEWS (GEN) showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a "brain drain" as foreign-born researchers educated in American universities will be more likely to leave.

Over 1600 professionals, from industry and academia, responded to the survey.

The largest majority, 57.11%, believe that the president-elect will hurt research funding. 24.26% said it would not make a difference, and 9.79% said Trump's presidency would prove positive.

One respondent expects, however, that industry will seek to outsource R&D to US academic labs: "If done wisely, perhaps there's a chance such a scheme could augment private funding for life science research."

During the campaign, Trump hinted at possible support for higher NIH budgets, even as he has called for cutting federal spending: "We must make the commitment to invest in science, engineering, healthcare and other areas that will make the lives of Americans better, safer and more prosperous," he has said.

51.74%, believe that science-technology-engineering-mathematics (STEM) will not be a priority under a Trump administration. 29.25% are uncertain, but 19.01% believe that a Trump administration will focus attention on STEM education.

"The biotechnology industry faces the possibility of a brain drain, and this is most alarming," said Mary Ann Liebert, founder and CEO of the 35 year old publication. A 46.78% plurality of respondents say they believed that foreign-born scientists who have been educated in the U.S. will be more likely to leave during a Trump presidency.

"GEN will continue to survey the field as Trump makes appointments in the cabinet and other positions, said Ms. Liebert. "The biotechnology community, like many others, was not prepared for a Trump victory; they must be on high alert to assure that one of this country's premier enterprises will not be compromised. In general, scientists are not political activists by nature, and this has to change."

A large plurality (49.81%) opined that overseas researchers will still seek academic positions or jobs in the US biotech industry; "but I think there will be fewer [of them applying]," a respondent predicted. 30.21% said they were uncertain, and 19.97%, disagreed.

While Trump has proposed allowing Medicare to negotiate drug prices as a means of lowering ever-rising prescription drug prices, and even called "pharma bro" Martin Shkreli, the Turing Pharmaceuticals' founder who received severe criticism earlier this year after raising the price of a toxoplasmosis therapy from $13.50 to $750 per pill, "a spoiled brat," close to half of respondents doubt that the president-elect will seek to contain those prices once he is sworn into office. Only 23.01% think Trump will do so, while twice that percentage (46.59%) believe he won't. The remaining 30.40% are uncertain. 56.22% of respondents believe a Trump presidency will affect the value of shares in publicly-traded biopharmas; 28.74% are uncertain, and 15.03% do not foresee any effect.

That view may have been swayed by yesterday's Wall Street rally, which reversed the stock selloff seen immediately after Trump won his electoral-vote majority. Three key exchange-traded funds for biotechs showed gains in the first trading day since Election Day: The iShares NASDAQ Biotechnology exchange traded fund (ETF) rose 9% to $284.99, as did the New York Stock Exchange Arca Biotechnology Index, which soared to $3,320.78, while the SPDR S&P Biotech ETF jumped 10% to $63.78.

"Values in publicly-traded companies will be affected, but I think that this will be mostly short- to intermediate-term," a survey respondent observed.

Opinions were more mixed on whether corporate funding of life sciences research will be impacted: 42.89% say it will, 26.22% say it won't, and 30.89% say they are uncertain.

Businesses would benefit, one respondent said, if Trump can lower the nation's corporate tax rate from 35% to 15%:

"Biopharma companies will remain located in the US rather than leaving to countries with lower tax rates. This will result in an increase in biopharma jobs and act as a magnet to bring international researchers to the US."

Whether Trump can achieve that tax cut, or other measures that benefit biopharma, remains uncertain.
Genetic Engineering & Biotechnology News, which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Translational Medicine.

Mary Ann Liebert, Inc./Genetic Engineering News

Related Biotechnology Articles:

The end of biotechnology as we know it
More than 400 attendees from five continents discussed trends and improvements in biotechnology at the European Summit of Industrial Biotechnology (ESIB) in Graz/Austria and talked many topics like a dehumanized research process.
Biotechnology: A growing field in the developing world
A detailed new report surveys a broad cross-section of biotechnology work across developing countries, revealing steady growth in fields tied to human well-being worldwide.
China releases first report on biotechnology in developing countries
The first report on biotechnology in developing countries revealing an overall picture of their biotechnology growth and competitiveness was released on Nov.
Exclusive: Biotechnology leaders surveyed about impact of Trump presidency
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by Genetic Engineering & Biotechnology News showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a 'brain drain' as foreign-born researchers educated in American universities will be more likely to leave.
Novel 'repair system' discovered in algae may yield new tools for biotechnology
The algae C. reinhardtii uses a novel system for releasing an interrupting sequence from a protein -- a technique that may be useful for protein purification.
ESIB -- European Summit of Industrial Biotechnology 2016
'Design' will be the guiding thread of the 2½ days ESIB 2016 which will cover trends in biotech science and industry, cascade design and metabolic engineering, designing nature (e.g. proteins for competitive bioprocesses), in-silico approaches in modern industrial biotechnology, networking opportunities and much more.
Werner Siemens Foundation fosters synthetic biotechnology
With its donation of 11.5 million euro, the Werner Siemens Foundation has facilitated the launch of the teaching and research domain Synthetic Biotechnology at the Technical University of Munich (TUM).
Sanyal Biotechnology LLC announces strategic partnership with OWL Metabolomics, S.L.
Sanyal Biotechnology LLC and One Way Liver S.L. (OWL Metabolomics) have initiated a strategic partnership to provide increased value and additional R&D services to basic research and the pharmaceutical industry, announced at the International Liver Congress in Barcelona, Spain.
ASU researcher improves crop performance with new biotechnology
Researchers with Arizona State University's School of Life Sciences have discovered a way to enhance a plant's tolerance to stress, which in turn improves how it uses water and nutrients from the soil.
New biotechnology to inhibit microRNA activity and novel applications
Today at the 45th Annual Meeting & Exhibition of the American Association for Dental Research, researcher Brad Amendt, University of Iowa, Iowa City, USA, will present a study titled 'New Biotechnology to Inhibit MicroRNA Activity and Novel Applications for Craniofacial and Dental Research.'

Related Biotechnology Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...